
16 October 2026 · Press release
NostraBiome announces NOSTRA-IO, a clinical study of continuous care for cancer patients on immunotherapy
A prospective, multicentre study following 100 patients treated with pembrolizumab for 6 months, with quality of life as the primary endpoint.
Read the press release
